Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
441-460 of 2,251 trials

Uveitis Treatment: Adalimumab vs. Mycophenolate Mofetil

We are studying whether adalimumab can improve outcomes for people with steroid-dependent non-infectious uveitis compared to the standard treatment. This trial will help us understand the effectiveness and safety of both medications.

Uveitis>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementOphthalmologyRheumatology

Cholestyramine for Obese Women: Pollutant Levels Study

We are exploring how cholestyramine treatment impacts harmful pollutant levels in obese women who may undergo bariatric surgery. This study aims to understand its effects before and after the surgery.

Epidermolysis Bullosa≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesDermatologyEndocrinologyInternal Medicine

IVF Luteal Phase Support: GnRH Agonist vs. hCG

We are studying whether a GnRH agonist can improve live birth rates and reduce miscarriages in women undergoing IVF compared to traditional hCG and progesterone support.

Assisted Reproductive Technology≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesGynecology and Obstetrics

Childhood Onset Nephrotic Syndrome: Obinutuzumab vs. MMF

We are studying whether obinutuzumab is more effective and safer than MMF for children with childhood onset idiopathic nephrotic syndrome. We will also look at how these treatments affect fatigue and quality of life.

Childhood Idiopathic Nephrotic Syndrome1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

S. aureus Bacteremia: Cloxacillin Dosing Study

We are investigating whether kidney function can help identify patients who may need adjusted doses of cloxacillin. This study aims to ensure safer and more effective treatment for those with S. aureus bacteremia.

Staphylococcus aureus BacteremiaMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesNephrology

Spinal Muscular Atrophy: Risdiplam for Children

We are studying the effectiveness and safety of risdiplam in children with spinal muscular atrophy who have not improved after gene therapy. This research aims to see if risdiplam can help these patients regain function.

Spinal Muscular Atrophy (SMA)>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPediatrics

Colon Cancer Treatment: Neo-Adjuvant Chemotherapy for Seniors

We are studying whether a 6-week chemotherapy treatment before surgery helps older adults with resectable colon cancer live longer and stay disease-free. This trial aims to personalize treatment for patients aged 70 and older.

Colon Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Acute Pancreatitis: Omega-3 Fatty Acid Infusion

We are studying whether early intravenous omega-3 fatty acids can help reduce organ failure and mortality in patients with acute pancreatitis. This trial compares the effects of omega-3s to standard medical care.

Severe Acute Pancreatitis6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesGastroenterologyInternal Medicine

Multiple Myeloma: Innovative Treatment Approaches

We are studying new methods to monitor multiple myeloma in patients who have not yet been treated. This trial compares different treatment combinations, including a stem cell transplant, to see which is more effective.

Multiple Myeloma6-12 monthsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Blood Pressure Response: Multi-Omics Study

We are exploring how specific biomarkers can predict the effectiveness of blood pressure medications for individuals. This study aims to improve treatment personalization and understand potential side effects.

Essential Hypertension3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine

COPD Treatment: Understanding ICS Response

We are studying how different eosinophil levels affect the response to inhaled corticosteroids in COPD patients. This research may help personalize treatment strategies for better management of the disease.

Chronic Obstructive Pulmonary Disease (COPD)1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyPulmonology

Heart Health: Adenosine Dose Study

We are investigating how different doses of adenosine affect blood flow in the heart for healthy individuals and patients with coronary artery disease. This study aims to understand if the response varies based on health status.

Chronic Ischemic Heart DiseaseMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Acute Myeloid Leukemia: MP0533 Treatment Study

We are testing a new drug, MP0533, for patients with acute myeloid leukemia or myelodysplastic syndrome. The study aims to evaluate its safety and how well it may work against these blood cancers.

Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)Safety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

High-Risk Retroperitoneal Sarcoma: Chemotherapy Before Surgery

We are testing whether chemotherapy before surgery improves outcomes for patients with high-risk retroperitoneal sarcoma. This study compares the effects of preoperative chemotherapy to surgery alone.

Dedifferentiated LiposarcomaLeiomyosarcoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Glioblastoma Treatment: Lomustine with or without Reirradiation

We are studying whether adding a second round of radiation to lomustine improves survival and quality of life for patients with recurrent glioblastoma. This trial aims to find out if this combination is more effective than lomustine alone.

Glioblastoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Treatment-Resistant Depression: COMP360 Study

We are studying whether two doses of COMP360 can improve symptoms in adults with treatment-resistant depression. This trial includes psychological support to enhance treatment effects.

Major Depressive DisorderTreatment-Resistant Depression6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Diffuse Large B-Cell Lymphoma: Epcoritamab with R-CHOP

We are studying whether adding Epcoritamab to standard R-CHOP treatment helps people with newly diagnosed Diffuse Large B-Cell Lymphoma live longer without disease progression. This trial compares the new combination to R-CHOP alone.

Diffuse Large B-Cell Lymphoma1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

JAK1 Inhibitor for Large Inflammatory Liver Adenomas

We are studying whether the oral medication baricitinib can help reduce the size of large inflammatory liver adenomas in patients. This trial also looks at the safety and effectiveness of this treatment compared to standard care.

Hepatocellular Adenoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyHepatology

Ofatumumab in Breast Milk: A Study for Lactating Women with MS

We are examining how much ofatumumab is found in the breast milk of mothers with relapsing multiple sclerosis. This research will help us understand the safety and effects on breastfeeding infants.

Multiple Sclerosis Relapse1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsNeurology

Advanced NSCLC: EXL-01 with Nivolumab

We are studying the combination of EXL-01 and nivolumab for patients with advanced non-small cell lung cancer who have not responded to prior immunotherapy. The trial aims to evaluate how well this combination works and its safety.

Non-small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncology